Najmeh Seifi MD, PhD, Hossein Bahari MSc, Elaheh Foroumandi PhD, Elahe Hasanpour BSc, Mahya Nikoumanesh BSc, Gordon A. Ferns MD, PhD, Habibollah Esmaily PhD, Majid Ghayour-Mobarhan MD, PhD
We aimed to investigate the association between an empirical dietary index for hyperinsulinemia (EDIH), empirical dietary index for insulin resistance (EDIR), and MetS and its components in an adult Iranian population. In this cross-sectional study, a total of 6482 participants aged 35–65 years were recruited as part of the MASHAD cohort study. Dietary intakes were assessed using a validated food frequency questionnaire (FFQ). The International Diabetes Federation (IDF) criteria were used to define MetS. Multivariable logistic regression models were applied to determine the association between EDIH, EDIR, and MetS and its components.
The mean age and BMI of participants were 48.44±8.20 years, and 27.98±4.73 kg/m2, respectively. Around 59% of the population was female. Of the total population, 35.4% had MetS. According to the full-adjusted model, there was no significant association between higher quartiles of EDIH and EDIR and odds of MetS (Q4 EDIH; OR (95%CI):0.93 (0.74-1.18), Q4 EDIR; OR (95%CI):1.14 (0.92-1.40). Regarding MetS components, EDIR was associated with increased odds of hypertension and diabetes (Q4 EDIR; OR (95%CI):1.22 (1.04-1.44) and 1.22 (1.01-1.47), respectively). EDIH was also associated with decreased odds of hypertriglyceridemia (Q4 EDIH; OR (95%CI): 0.72 (0.60-0.87)). This study showed no significant association between hyperinsulinemia and insulin resistance potential of diet and odds of MetS among Iranian adults. However, EDIR was significantly associated with increased odds of hypertension and diabetes as MetS components.
{"title":"The association of dietary indices for hyperinsulinemia and insulin resistance with the risk of metabolic syndrome: a population-based cross-sectional study","authors":"Najmeh Seifi MD, PhD, Hossein Bahari MSc, Elaheh Foroumandi PhD, Elahe Hasanpour BSc, Mahya Nikoumanesh BSc, Gordon A. Ferns MD, PhD, Habibollah Esmaily PhD, Majid Ghayour-Mobarhan MD, PhD","doi":"10.1111/jch.14832","DOIUrl":"10.1111/jch.14832","url":null,"abstract":"<p>We aimed to investigate the association between an empirical dietary index for hyperinsulinemia (EDIH), empirical dietary index for insulin resistance (EDIR), and MetS and its components in an adult Iranian population. In this cross-sectional study, a total of 6482 participants aged 35–65 years were recruited as part of the MASHAD cohort study. Dietary intakes were assessed using a validated food frequency questionnaire (FFQ). The International Diabetes Federation (IDF) criteria were used to define MetS. Multivariable logistic regression models were applied to determine the association between EDIH, EDIR, and MetS and its components.</p><p>The mean age and BMI of participants were 48.44±8.20 years, and 27.98±4.73 kg/m<sup>2</sup>, respectively. Around 59% of the population was female. Of the total population, 35.4% had MetS. According to the full-adjusted model, there was no significant association between higher quartiles of EDIH and EDIR and odds of MetS (Q4 EDIH; OR (95%CI):0.93 (0.74-1.18), Q4 EDIR; OR (95%CI):1.14 (0.92-1.40). Regarding MetS components, EDIR was associated with increased odds of hypertension and diabetes (Q4 EDIR; OR (95%CI):1.22 (1.04-1.44) and 1.22 (1.01-1.47), respectively). EDIH was also associated with decreased odds of hypertriglyceridemia (Q4 EDIH; OR (95%CI): 0.72 (0.60-0.87)). This study showed no significant association between hyperinsulinemia and insulin resistance potential of diet and odds of MetS among Iranian adults. However, EDIR was significantly associated with increased odds of hypertension and diabetes as MetS components.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 7","pages":"832-841"},"PeriodicalIF":2.7,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.14832","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141514438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adequate management of nocturnal hypertension is crucial to reduce the risk of organ damage and cardiovascular events. The EARLY-NH study was a prospective, open-label, multicenter study conducted in Japanese patients with nocturnal hypertension who received esaxerenone treatment for 12 weeks. This post hoc analysis aimed to assess (1) the relationship between changes in morning home systolic blood pressure (SBP), bedtime home SBP, and nighttime home SBP based on changes in SBP and achievement rates of target SBP levels; and (2) the correlation between nighttime home SBP measurements using brachial and wrist home BP monitoring (HBPM) devices. This analysis evaluated 82 patients who completed the 12-week treatment period. Among those who achieved target morning home SBP (<135 mmHg) and target bedtime home SBP (<135 mmHg), the brachial HBPM device showed achievement rates of 63.6% and 56.4%, respectively, for target nighttime home SBP (<120 mmHg). The wrist device showed achievement rates of 66.7% and 63.4%, respectively, for the same targets. Significant correlations were observed between both devices for nighttime home SBP measurements at baseline (r = 0.790), Week 12 (r = 0.641), and change from baseline to Week 12 (r = 0.533) (all, p < .001). In this patient population, approximately 60% of individuals who reached target morning or bedtime home SBP levels <135 mmHg exhibited well-controlled nighttime home SBP. Although nighttime home SBP measurements obtained using both brachial and wrist HBPM devices displayed a significant correlation, the wrist device needs to be examined in more detail for clinical use.
{"title":"Antihypertensive effect of esaxerenone and correlation between brachial and wrist home monitoring devices in patients with nocturnal hypertension: A post hoc analysis of the EARLY-NH study","authors":"Kazuomi Kario MD, PhD, Kazuhito Shiosakai MS, Takashi Taguchi PhD","doi":"10.1111/jch.14857","DOIUrl":"10.1111/jch.14857","url":null,"abstract":"<p>Adequate management of nocturnal hypertension is crucial to reduce the risk of organ damage and cardiovascular events. The EARLY-NH study was a prospective, open-label, multicenter study conducted in Japanese patients with nocturnal hypertension who received esaxerenone treatment for 12 weeks. This post hoc analysis aimed to assess (1) the relationship between changes in morning home systolic blood pressure (SBP), bedtime home SBP, and nighttime home SBP based on changes in SBP and achievement rates of target SBP levels; and (2) the correlation between nighttime home SBP measurements using brachial and wrist home BP monitoring (HBPM) devices. This analysis evaluated 82 patients who completed the 12-week treatment period. Among those who achieved target morning home SBP (<135 mmHg) and target bedtime home SBP (<135 mmHg), the brachial HBPM device showed achievement rates of 63.6% and 56.4%, respectively, for target nighttime home SBP (<120 mmHg). The wrist device showed achievement rates of 66.7% and 63.4%, respectively, for the same targets. Significant correlations were observed between both devices for nighttime home SBP measurements at baseline (<i>r</i> = 0.790), Week 12 (<i>r</i> = 0.641), and change from baseline to Week 12 (<i>r</i> = 0.533) (all, <i>p</i> < .001). In this patient population, approximately 60% of individuals who reached target morning or bedtime home SBP levels <135 mmHg exhibited well-controlled nighttime home SBP. Although nighttime home SBP measurements obtained using both brachial and wrist HBPM devices displayed a significant correlation, the wrist device needs to be examined in more detail for clinical use.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 7","pages":"842-849"},"PeriodicalIF":2.7,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.14857","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141514439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bonaventure Oguaju MBBS, Darren Lau MD, PhD, Raj Padwal MD, MSc, Jennifer Ringrose MD, MSc
Accurate arm circumference (AC) measurement is required for accurate blood pressure (BP) readings. Standards stipulate measuring arm circumference at the midpoint between the acromion process (AP) and the olecranon process. However, which part of the AP to use is not stipulated. Furthermore, BP is measured sitting but arm circumference is measured standing. We sought to understand how landmarking during AC measurement and body position affect cuff size selection. Two variations in measurement procedure were studied. First, AC was measured at the top of the acromion (TOA) and compared to the spine of the acromion (SOA). Second, standing versus seated measurements using each landmark were compared. AC was measured to the nearest 0.1 cm at the mid-point of the upper arm by two independent observers, blinded from each other's measurements. In 51 participants, the mean (±SD) mid-AC measurement using the anchoring landmarks TOA and SOA in the standing position were 32.4 cm (±6.18) and 32.1 cm (±6.07), respectively (mean difference of 0.3 cm). In the seated position, mean arm circumference was 32.2 (±6.10) using TOA and 31.1 (±6.03) using SOA (mean difference 1.1 cm). Kappa agreement for cuff selection in the standing position between TOA and SOA was 0.94 (p < 0.001). The landmark on the acromion process can change the cuff selection in a small percentage of cases. The overall impact of this landmark selection is small. However, standardizing landmark selection and body position for AC measurement could further reduce variability in cuff size selection during BP measurement and validation studies.
要准确读取血压 (BP) 值,就必须精确测量臂围 (AC)。标准规定在肩峰突起(AP)和肩胛突起之间的中点测量臂围。但是,没有规定使用肩峰突起的哪个部位。此外,血压是坐着测量的,而臂围是站着测量的。我们试图了解测量臂围时的标记和身体姿势如何影响袖带尺寸的选择。我们研究了两种不同的测量程序。首先,在肩峰顶部(TOA)测量 AC 值,并与肩峰脊柱(SOA)进行比较。其次,比较了使用每个地标进行的站立和坐姿测量。由两名独立的观察者在上臂中点测量 AC 值,精确到 0.1 厘米,并对彼此的测量结果进行盲测。在 51 名参与者中,站立姿势下使用锚定地标 TOA 和 SOA 测量的平均(±SD)AC 中点分别为 32.4 厘米(±6.18)和 32.1 厘米(±6.07)(平均差异为 0.3 厘米)。在坐位时,使用 TOA 的平均臂围为 32.2(±6.10)厘米,使用 SOA 的平均臂围为 31.1(±6.03)厘米(平均相差 1.1 厘米)。在站立位置选择袖带时,TOA 和 SOA 的 Kappa 一致性为 0.94(p < 0.001)。在一小部分病例中,肩峰突上的地标会改变袖带选择。该地标选择的总体影响较小。然而,在测量 AC 时将地标选择和体位标准化可进一步减少血压测量和验证研究中袖带尺寸选择的变异性。
{"title":"Inter-observer reliability and anatomical landmarks for arm circumference to determine cuff size for blood pressure measurement","authors":"Bonaventure Oguaju MBBS, Darren Lau MD, PhD, Raj Padwal MD, MSc, Jennifer Ringrose MD, MSc","doi":"10.1111/jch.14854","DOIUrl":"10.1111/jch.14854","url":null,"abstract":"<p>Accurate arm circumference (AC) measurement is required for accurate blood pressure (BP) readings. Standards stipulate measuring arm circumference at the midpoint between the acromion process (AP) and the olecranon process. However, which part of the AP to use is not stipulated. Furthermore, BP is measured sitting but arm circumference is measured standing. We sought to understand how landmarking during AC measurement and body position affect cuff size selection. Two variations in measurement procedure were studied. First, AC was measured at the top of the acromion (TOA) and compared to the spine of the acromion (SOA). Second, standing versus seated measurements using each landmark were compared. AC was measured to the nearest 0.1 cm at the mid-point of the upper arm by two independent observers, blinded from each other's measurements. In 51 participants, the mean (±SD) mid-AC measurement using the anchoring landmarks TOA and SOA in the standing position were 32.4 cm (±6.18) and 32.1 cm (±6.07), respectively (mean difference of 0.3 cm). In the seated position, mean arm circumference was 32.2 (±6.10) using TOA and 31.1 (±6.03) using SOA (mean difference 1.1 cm). Kappa agreement for cuff selection in the standing position between TOA and SOA was 0.94 (<i>p</i> < 0.001). The landmark on the acromion process can change the cuff selection in a small percentage of cases. The overall impact of this landmark selection is small. However, standardizing landmark selection and body position for AC measurement could further reduce variability in cuff size selection during BP measurement and validation studies.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 7","pages":"867-871"},"PeriodicalIF":2.7,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jch.14854","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141510213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kaiyin Li MD, Lan Gao MD, Yimeng Jiang MD, Jia Jia MPH, Jianping Li MD, Fangfang Fan MD, Yan Zhang MD, Yong Huo MD
Central blood pressure confers cardiovascular risk prediction ability, but whether the association between central systolic blood pressure (cSBP) and cardiovascular endpoints is independent of peripheral systolic blood pressure (pSBP) remains controversial. This systematic review and meta-analysis aim to investigate the associations between cSBP and cardiovascular endpoints in models including and excluding pSBP, respectively. Observational studies assessing the risk of composite cardiovascular endpoints with baseline cSBP were searched in PubMed, Embase, Scopus, Web of Science, and Cochrane Library to May 31, 2022. Risk of bias was assessed by the Newcastle-Ottawa Quality Assessment Scale, and random-effects models were used to pool estimates. Finally, 48 200 participants from 19 studies with a mean age of 59.0 ± 6.9 years were included. Per 10 mmHg increase of cSBP was associated with higher risk of composite cardiovascular outcomes (risk ratio [RR]: 1.14 [95%CI 1.08–1.19]) and cardiovascular death (RR: 1.18 [95%CI 1.08–1.30]), and the associations still existed after adjusting for pSBP (RR: 1.13 [95%CI 1.05–1.21] for composite cardiovascular endpoints; RR: 1.25 [95%CI 1.09–1.43] for cardiovascular death). In pSBP-unadjusted studies, increased cSBP was also associated with higher risk of all-cause mortality and stroke, but not in the pSBP-adjusted studies. Both cSBP and pSBP were similarly significantly associated with composite cardiovascular endpoints in models containing them separately and simultaneously. cSBP was significantly associated with cardiovascular events, independently of pSBP. Central or peripheral SBP could supplement cardiovascular risk assessment besides each other.
{"title":"Association of cardiovascular events with central systolic blood pressure: A systemic review and meta-analysis","authors":"Kaiyin Li MD, Lan Gao MD, Yimeng Jiang MD, Jia Jia MPH, Jianping Li MD, Fangfang Fan MD, Yan Zhang MD, Yong Huo MD","doi":"10.1111/jch.14853","DOIUrl":"10.1111/jch.14853","url":null,"abstract":"<p>Central blood pressure confers cardiovascular risk prediction ability, but whether the association between central systolic blood pressure (cSBP) and cardiovascular endpoints is independent of peripheral systolic blood pressure (pSBP) remains controversial. This systematic review and meta-analysis aim to investigate the associations between cSBP and cardiovascular endpoints in models including and excluding pSBP, respectively. Observational studies assessing the risk of composite cardiovascular endpoints with baseline cSBP were searched in PubMed, Embase, Scopus, Web of Science, and Cochrane Library to May 31, 2022. Risk of bias was assessed by the Newcastle-Ottawa Quality Assessment Scale, and random-effects models were used to pool estimates. Finally, 48 200 participants from 19 studies with a mean age of 59.0 ± 6.9 years were included. Per 10 mmHg increase of cSBP was associated with higher risk of composite cardiovascular outcomes (risk ratio [RR]: 1.14 [95%CI 1.08–1.19]) and cardiovascular death (RR: 1.18 [95%CI 1.08–1.30]), and the associations still existed after adjusting for pSBP (RR: 1.13 [95%CI 1.05–1.21] for composite cardiovascular endpoints; RR: 1.25 [95%CI 1.09–1.43] for cardiovascular death). In pSBP-unadjusted studies, increased cSBP was also associated with higher risk of all-cause mortality and stroke, but not in the pSBP-adjusted studies. Both cSBP and pSBP were similarly significantly associated with composite cardiovascular endpoints in models containing them separately and simultaneously. cSBP was significantly associated with cardiovascular events, independently of pSBP. Central or peripheral SBP could supplement cardiovascular risk assessment besides each other.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 7","pages":"747-756"},"PeriodicalIF":2.7,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Knowledge of the status of real-world home blood pressure (BP) measurements is crucial for establishing policies promoting hypertension treatment through home BP monitoring. However, only a few studies have investigated the status of home BP measurements in real-world settings. This study investigated the practice of Korean patients in measuring BP at home. This study recruited participants aged ≥20 years who were taking antihypertensives and conducted a questionnaire-based survey on home BP measurements. Of 701 participants recruited between August 2018 and April 2020, 673 were included in the analysis. Of these, 359 (53.3%) possessed home BP measurement devices. The devices used by 184 (51.3%) participants were validated, 110 (30.6%) were nonvalidated, and 65 (18.1%) had an unknown validation status. Only 18 patients (5.0%) with home BP devices were aware of the validation tests for home BP measurement devices. Of the 673 participants, 278 (41.3%) measured BP at home (77.4% of the patients owned home BP measurement devices). Among them, at least 74 (26.6%) performed proper measurements (at least once a month, at least twice a day or twice at a time, after at least 1 minute of rest, with at least a 1-min interval between each measurement, and 30 min after drinking coffee, exercising, or smoking). In conclusion, our community-based survey in the nonpresentive Korean population revealed a low rate of home BP measurement, a high rate of using nonvalidated devices, and a high rate of inappropriate measurements, suggesting that more efforts toward patient education regarding home BP measurements are needed.
{"title":"Status of home blood pressure measurement in treated hypertensive patients. Results of a survey from two cities in Korea","authors":"Kyung-ju Lee MD, Moo-Yong Rhee MD, PhD","doi":"10.1111/jch.14808","DOIUrl":"10.1111/jch.14808","url":null,"abstract":"<p>Knowledge of the status of real-world home blood pressure (BP) measurements is crucial for establishing policies promoting hypertension treatment through home BP monitoring. However, only a few studies have investigated the status of home BP measurements in real-world settings. This study investigated the practice of Korean patients in measuring BP at home. This study recruited participants aged ≥20 years who were taking antihypertensives and conducted a questionnaire-based survey on home BP measurements. Of 701 participants recruited between August 2018 and April 2020, 673 were included in the analysis. Of these, 359 (53.3%) possessed home BP measurement devices. The devices used by 184 (51.3%) participants were validated, 110 (30.6%) were nonvalidated, and 65 (18.1%) had an unknown validation status. Only 18 patients (5.0%) with home BP devices were aware of the validation tests for home BP measurement devices. Of the 673 participants, 278 (41.3%) measured BP at home (77.4% of the patients owned home BP measurement devices). Among them, at least 74 (26.6%) performed proper measurements (at least once a month, at least twice a day or twice at a time, after at least 1 minute of rest, with at least a 1-min interval between each measurement, and 30 min after drinking coffee, exercising, or smoking). In conclusion, our community-based survey in the nonpresentive Korean population revealed a low rate of home BP measurement, a high rate of using nonvalidated devices, and a high rate of inappropriate measurements, suggesting that more efforts toward patient education regarding home BP measurements are needed.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 7","pages":"825-831"},"PeriodicalIF":2.7,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>Dear Editor,</p><p>We would like to discuss “Enhancing clinical decision-making: Optimizing ChatGPT's performance in hypertension care.<span><sup>1</sup></span>” Artificial intelligence, particularly conversational models such as OpenAI's ChatGPT, has profoundly impacted several industries, including the healthcare sector. It is a useful tool in medical research and treatment because of its capacity to analyze large volumes of data and mimic human speech. With its ability to provide recommendations and individualized health monitoring, ChatGPT holds great potential to transform patient care. For best usage in healthcare settings, there are still several areas where it falls short, such as the use of dated data and the absence of clinical judgment and individualized treatment suggestions.</p><p>One new highlight is the potential enhancements and optimizations that ChatGPT could bring to hypertension management. By summarizing guidelines, updating information, and providing decision support tools, ChatGPT can improve diagnostic accuracy, tailor treatments, and ultimately enhance patient outcomes. Additionally, as an education tool, ChatGPT can simplify complex medical topics for both patients and healthcare professionals, fostering ongoing learning and improving clinical reasoning. Research and evidence synthesis capabilities of ChatGPT can help healthcare providers make informed clinical decisions through concise overviews of the latest studies and treatments in hypertension management. The fact that ChatGPT may produce incoherent and unhelpful results is a prevalent concern. Temsah et al. stated that because of their unreliability, the present forms of ChatGPT and other Chatbots should not be employed for diagnostic or treatment purposes without human expert oversight.<span><sup>2</sup></span></p><p>Future directions for ChatGPT in hypertension care include increasing its performance by selecting advanced models, customizing user profiles, and integrating clinical guidelines. Staying updated with research findings, creating a feedback loop for continuous improvement, and complementing professional judgment are essential steps for maximizing the utility of ChatGPT in clinical decision-making. Ethical considerations and limitations, such as privacy and security concerns, should also be addressed when using AI tools in healthcare settings. Collaborative efforts among technology developers, healthcare professionals, and patients are crucial for tailoring ChatGPT to meet the diverse needs of all stakeholders and optimizing patient care in the future.</p><p>Another obstacle to integration is the potential for bias in AI algorithms. If the data used to train the LLMs is not representative of all patient populations, it can lead to inaccurate or discriminatory outcomes. To address this issue, efforts must be made to ensure diverse and inclusive datasets are used in training AI algorithms. Regular audits and monitoring of AI systems can also help ident
{"title":"Optimizing ChatGPT's performance in hypertension care: Correspondence","authors":"Hinpetch Daungsupawong PhD, Viroj Wiwanitkit MD","doi":"10.1111/jch.14850","DOIUrl":"10.1111/jch.14850","url":null,"abstract":"<p>Dear Editor,</p><p>We would like to discuss “Enhancing clinical decision-making: Optimizing ChatGPT's performance in hypertension care.<span><sup>1</sup></span>” Artificial intelligence, particularly conversational models such as OpenAI's ChatGPT, has profoundly impacted several industries, including the healthcare sector. It is a useful tool in medical research and treatment because of its capacity to analyze large volumes of data and mimic human speech. With its ability to provide recommendations and individualized health monitoring, ChatGPT holds great potential to transform patient care. For best usage in healthcare settings, there are still several areas where it falls short, such as the use of dated data and the absence of clinical judgment and individualized treatment suggestions.</p><p>One new highlight is the potential enhancements and optimizations that ChatGPT could bring to hypertension management. By summarizing guidelines, updating information, and providing decision support tools, ChatGPT can improve diagnostic accuracy, tailor treatments, and ultimately enhance patient outcomes. Additionally, as an education tool, ChatGPT can simplify complex medical topics for both patients and healthcare professionals, fostering ongoing learning and improving clinical reasoning. Research and evidence synthesis capabilities of ChatGPT can help healthcare providers make informed clinical decisions through concise overviews of the latest studies and treatments in hypertension management. The fact that ChatGPT may produce incoherent and unhelpful results is a prevalent concern. Temsah et al. stated that because of their unreliability, the present forms of ChatGPT and other Chatbots should not be employed for diagnostic or treatment purposes without human expert oversight.<span><sup>2</sup></span></p><p>Future directions for ChatGPT in hypertension care include increasing its performance by selecting advanced models, customizing user profiles, and integrating clinical guidelines. Staying updated with research findings, creating a feedback loop for continuous improvement, and complementing professional judgment are essential steps for maximizing the utility of ChatGPT in clinical decision-making. Ethical considerations and limitations, such as privacy and security concerns, should also be addressed when using AI tools in healthcare settings. Collaborative efforts among technology developers, healthcare professionals, and patients are crucial for tailoring ChatGPT to meet the diverse needs of all stakeholders and optimizing patient care in the future.</p><p>Another obstacle to integration is the potential for bias in AI algorithms. If the data used to train the LLMs is not representative of all patient populations, it can lead to inaccurate or discriminatory outcomes. To address this issue, efforts must be made to ensure diverse and inclusive datasets are used in training AI algorithms. Regular audits and monitoring of AI systems can also help ident","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 7","pages":"872-873"},"PeriodicalIF":2.7,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study examines hypertension control beyond the cascade of care framework, which assesses awareness, treatment, and control sequentially. The analysis included 52 434 hypertensive adults (blood pressure (BP) ≥140/90 mm Hg and/or treatment in the past 6 months), aged 25–69, from the French population-based CONSTANCES cohort from 2012 to 2021. The authors assessed the typical “awareness, treatment, and control” scenario and characterized other possible control patterns. The authors found that 13% achieved control. This percentage rose to 19% when considering individuals who were not aware but treated and controlled. This alternative control scenario was associated with female sex, younger age, higher education, Northern-African origin, and reporting prior cardiovascular diseases (CVD). Sub-Saharan African origin, diabetes and overweight/obesity were associated with the typical control scenario. This study highlights that applying a typical sequential cascade of care approach may lead to the exclusion of some specific groups of participants who do not fit into the defined categories.
{"title":"Unveiling the gaps: Hypertension control beyond the cascade of care framework","authors":"Léna Silberzan MSc, Nathalie Bajos PhD, Michelle Kelly-Irving PhD","doi":"10.1111/jch.14849","DOIUrl":"10.1111/jch.14849","url":null,"abstract":"<p>This study examines hypertension control beyond the cascade of care framework, which assesses awareness, treatment, and control sequentially. The analysis included 52 434 hypertensive adults (blood pressure (BP) ≥140/90 mm Hg and/or treatment in the past 6 months), aged 25–69, from the French population-based CONSTANCES cohort from 2012 to 2021. The authors assessed the typical “awareness, treatment, and control” scenario and characterized other possible control patterns. The authors found that 13% achieved control. This percentage rose to 19% when considering individuals who were not aware but treated and controlled. This alternative control scenario was associated with female sex, younger age, higher education, Northern-African origin, and reporting prior cardiovascular diseases (CVD). Sub-Saharan African origin, diabetes and overweight/obesity were associated with the typical control scenario. This study highlights that applying a typical sequential cascade of care approach may lead to the exclusion of some specific groups of participants who do not fit into the defined categories.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 7","pages":"861-866"},"PeriodicalIF":2.7,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sebastian Lindblom PhD, Charlotte Ivarsson MSc, Per Wändell MD, PhD, Monica Bergqvist PhD, Anders Norrman MD, Julia Eriksson MSc, Lena Lund PhD, Maria Hagströmer PhD, Jan Hasselström MD, PhD, Christina Sandlund PhD, Axel C Carlsson PhD
The study aimed to investigate differences in hypertensive- and cardio-preventive pharmacotherapy depending on if patients with hypertension received lifestyle counseling or not, including the difference between men and women. Data from the Region Stockholm VAL database was used to identify all patients with a hypertension diagnosis and had visited a primary health care center within the past five years. Data included registered diagnoses, pharmacotherapy, and codes for lifestyle counseling. Logistic regression adjusted for age and comorbidity (diabetes, stroke, coronary heart disease, atrial fibrillation, gout, obesity, heart failure) was used, presenting results as odds ratios (OR) with 99% confidence interval (CI). The study included 130,030 patients with hypertension; 63,402 men and 66,628 women. Patients receiving recommended lifestyle counseling were more frequently treated with three or more hypertensive drugs: women OR 1.38 (1.31, 1.45) and men = 1.36 (1.30, 1.43); certain drug classes: calcium antagonists: women 1.09 (1.04, 1.14) and men 1.11 (1.06, 1.16); thiazide diuretics: women 1.26 (1.20, 1.34) and men 1.25 (1.19, 1.32); and aldosterone antagonists: women 1.25 (1.12, 1.41) and men 1.49 (1.34, 1.65). Patients receiving recommended level of lifestyle counseling with concomitant coronary heart disease, atrial fibrillation, diabetes, or stroke were more frequently treated with statins than those who did not. Further, recommended lifestyle counseling was significantly associated with anticoagulant treatment in patients with atrial fibrillation. Lifestyle counseling according to recommendations in national guidelines was significantly associated with a more thorough pharmacological treatment of hypertension, statins, and antithrombotic drugs as well as anticoagulants, in both men and women.
该研究旨在调查高血压患者是否接受生活方式咨询对高血压和心脏预防药物治疗的影响,包括男女之间的差异。研究使用斯德哥尔摩地区 VAL 数据库中的数据,对所有确诊为高血压并在过去五年内就诊于初级医疗保健中心的患者进行识别。数据包括登记的诊断、药物治疗和生活方式咨询代码。采用逻辑回归法对年龄和合并症(糖尿病、中风、冠心病、心房颤动、痛风、肥胖、心力衰竭)进行调整,结果以几率比(OR)表示,置信区间(CI)为 99%。该研究包括 130,030 名高血压患者,其中男性 63,402 人,女性 66,628 人。接受建议的生活方式咨询的患者更常接受三种或三种以上高血压药物治疗:女性 OR 1.38(1.31,1.45),男性 = 1.36(1.30,1.43);某些药物类别:钙拮抗剂:女性 1.09(1.04,1.14),男性 1.11(1.06,1.16);噻嗪类利尿剂:女性 1.26(1.20,1.34),男性 1.25(1.19,1.32);醛固酮拮抗剂:女性 1.25(1.12,1.41),男性 1.49(1.34,1.65)。同时患有冠心病、心房颤动、糖尿病或中风并接受了推荐水平生活方式咨询的患者比未接受咨询的患者更常接受他汀类药物治疗。此外,推荐的生活方式咨询与心房颤动患者的抗凝治疗有显著相关性。根据国家指南中的建议提供生活方式咨询与更彻底的高血压药物治疗、他汀类药物、抗血栓药物以及抗凝药物治疗有显著相关性,男性和女性均是如此。
{"title":"Lifestyle counseling in patients with hypertension in primary health care and its association with antihypertensive pharmacotherapy","authors":"Sebastian Lindblom PhD, Charlotte Ivarsson MSc, Per Wändell MD, PhD, Monica Bergqvist PhD, Anders Norrman MD, Julia Eriksson MSc, Lena Lund PhD, Maria Hagströmer PhD, Jan Hasselström MD, PhD, Christina Sandlund PhD, Axel C Carlsson PhD","doi":"10.1111/jch.14852","DOIUrl":"10.1111/jch.14852","url":null,"abstract":"<p>The study aimed to investigate differences in hypertensive- and cardio-preventive pharmacotherapy depending on if patients with hypertension received lifestyle counseling or not, including the difference between men and women. Data from the Region Stockholm VAL database was used to identify all patients with a hypertension diagnosis and had visited a primary health care center within the past five years. Data included registered diagnoses, pharmacotherapy, and codes for lifestyle counseling. Logistic regression adjusted for age and comorbidity (diabetes, stroke, coronary heart disease, atrial fibrillation, gout, obesity, heart failure) was used, presenting results as odds ratios (OR) with 99% confidence interval (CI). The study included 130,030 patients with hypertension; 63,402 men and 66,628 women. Patients receiving recommended lifestyle counseling were more frequently treated with three or more hypertensive drugs: women OR 1.38 (1.31, 1.45) and men = 1.36 (1.30, 1.43); certain drug classes: calcium antagonists: women 1.09 (1.04, 1.14) and men 1.11 (1.06, 1.16); thiazide diuretics: women 1.26 (1.20, 1.34) and men 1.25 (1.19, 1.32); and aldosterone antagonists: women 1.25 (1.12, 1.41) and men 1.49 (1.34, 1.65). Patients receiving recommended level of lifestyle counseling with concomitant coronary heart disease, atrial fibrillation, diabetes, or stroke were more frequently treated with statins than those who did not. Further, recommended lifestyle counseling was significantly associated with anticoagulant treatment in patients with atrial fibrillation. Lifestyle counseling according to recommendations in national guidelines was significantly associated with a more thorough pharmacological treatment of hypertension, statins, and antithrombotic drugs as well as anticoagulants, in both men and women.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 7","pages":"816-824"},"PeriodicalIF":2.7,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emmanuel Adediran MPH, Robert Owens PhD, Elena Gardner MPH, Alex Lockrey B.Sc, Emily Carlson MHA, Danielle Forbes MPH, John Stuligross MPH, Dominik Ose DrPH
Hypertension disparities persist and remain high among racial and ethnic minority populations in the United States (US). Data-driven approaches based on electronic health records (EHRs) in primary care are seen as a strong opportunity to address this situation. This qualitative study evaluated the development, sustainability, and usability of an EHR-integrated hypertension disparities dashboard for health care professionals in primary care. Ten semi-structured interviews, exploring the approach and sustainability, as well as eight usability interviews, using the think aloud protocol were conducted with quality improvement managers, data analysts, program managers, evaluators, and primary care providers. For the results, dashboard development steps include having clear goals, defining a target audience, compiling data, and building multidisciplinary teams. For sustainability, the dashboard can enhance understanding of the social determinants of health or to inform QI projects. In terms of dashboard usability, positive aspects consisted of the inclusion of summary pages, patient's detail pages, and hover-over interface. Important design considerations were refining sorting functions, gender inclusivity, and increasing dashboard visibility. In sum, an EHR-driven dashboard can be a novel tool for addressing hypertension disparities in primary care. It offers a platform where clinicians can identify patients for culturally tailored interventions. Factors such as physician time constraints, data definitions, comprehensive patient demographic information, end-users, and future sustenance, should be considered before implementing a dashboard. Additional research is needed to identify practices for integrating a dashboard into clinical workflow for hypertension.
{"title":"Development and usability of an EHR-driven hypertension disparities dashboard in primary care: A qualitative study","authors":"Emmanuel Adediran MPH, Robert Owens PhD, Elena Gardner MPH, Alex Lockrey B.Sc, Emily Carlson MHA, Danielle Forbes MPH, John Stuligross MPH, Dominik Ose DrPH","doi":"10.1111/jch.14834","DOIUrl":"10.1111/jch.14834","url":null,"abstract":"<p>Hypertension disparities persist and remain high among racial and ethnic minority populations in the United States (US). Data-driven approaches based on electronic health records (EHRs) in primary care are seen as a strong opportunity to address this situation. This qualitative study evaluated the development, sustainability, and usability of an EHR-integrated hypertension disparities dashboard for health care professionals in primary care. Ten semi-structured interviews, exploring the approach and sustainability, as well as eight usability interviews, using the think aloud protocol were conducted with quality improvement managers, data analysts, program managers, evaluators, and primary care providers. For the results, dashboard development steps include having clear goals, defining a target audience, compiling data, and building multidisciplinary teams. For sustainability, the dashboard can enhance understanding of the social determinants of health or to inform QI projects. In terms of dashboard usability, positive aspects consisted of the inclusion of summary pages, patient's detail pages, and hover-over interface. Important design considerations were refining sorting functions, gender inclusivity, and increasing dashboard visibility. In sum, an EHR-driven dashboard can be a novel tool for addressing hypertension disparities in primary care. It offers a platform where clinicians can identify patients for culturally tailored interventions. Factors such as physician time constraints, data definitions, comprehensive patient demographic information, end-users, and future sustenance, should be considered before implementing a dashboard. Additional research is needed to identify practices for integrating a dashboard into clinical workflow for hypertension.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 7","pages":"797-805"},"PeriodicalIF":2.7,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia and is an important risk factor for ischemic cerebrovascular events. This study used machine learning techniques to develop and validate a new risk prediction model for new-onset AF that incorporated the use electrocardiogram to diagnose AF, data from participants with a wide age range, and considered hypertension and measures of atrial stiffness. In Japan, Industrial Safety and Health Law requires employers to provide annual health check-ups to their employees. This study included 13 410 individuals who underwent health check-ups on at least four successive years between 2005 and 2015 (new-onset AF, n = 110; non-AF, n = 13 300). Data were entered into a risk prediction model using machine learning methods (eXtreme Gradient Boosting and Shapley Additive Explanation values). Data were randomly split into a training set (80%) used for model construction and development, and a test set (20%) used to test performance of the derived model. The area under the receiver operator characteristic curve for the model in the test set was 0.789. The best predictor of new-onset AF was age, followed by the cardio-ankle vascular index, estimated glomerular filtration rate, sex, body mass index, uric acid, γ-glutamyl transpeptidase level, triglycerides, systolic blood pressure at cardio-ankle vascular index measurement, and alanine aminotransferase level. This new model including arterial stiffness measure, developed with data from a general population using machine learning methods, could be used to identify at-risk individuals and potentially facilitation the prevention of future AF development.
{"title":"Precise risk-prediction model including arterial stiffness for new-onset atrial fibrillation using machine learning techniques","authors":"Hiroshi Kanegae BSc, Kentaro Fujishiro MD, PhD, Kyohei Fukatani MBA, Tetsuya Ito MEng, Kazuomi Kario MD, PhD","doi":"10.1111/jch.14848","DOIUrl":"10.1111/jch.14848","url":null,"abstract":"<p>Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia and is an important risk factor for ischemic cerebrovascular events. This study used machine learning techniques to develop and validate a new risk prediction model for new-onset AF that incorporated the use electrocardiogram to diagnose AF, data from participants with a wide age range, and considered hypertension and measures of atrial stiffness. In Japan, Industrial Safety and Health Law requires employers to provide annual health check-ups to their employees. This study included 13 410 individuals who underwent health check-ups on at least four successive years between 2005 and 2015 (new-onset AF, <i>n</i> = 110; non-AF, <i>n</i> = 13 300). Data were entered into a risk prediction model using machine learning methods (eXtreme Gradient Boosting and Shapley Additive Explanation values). Data were randomly split into a training set (80%) used for model construction and development, and a test set (20%) used to test performance of the derived model. The area under the receiver operator characteristic curve for the model in the test set was 0.789. The best predictor of new-onset AF was age, followed by the cardio-ankle vascular index, estimated glomerular filtration rate, sex, body mass index, uric acid, γ-glutamyl transpeptidase level, triglycerides, systolic blood pressure at cardio-ankle vascular index measurement, and alanine aminotransferase level. This new model including arterial stiffness measure, developed with data from a general population using machine learning methods, could be used to identify at-risk individuals and potentially facilitation the prevention of future AF development.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":"26 7","pages":"806-815"},"PeriodicalIF":2.7,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}